Beamtree Holdings Limited (ASX:BMT) provides AI decision support and data insights solutions for hospitals and pathology laboratories. The company combines clinical, coding and data expertise.
INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics based on proprietary exosome technologies. The company’s portfolio includes commercial exosome isolation products, cancer diagnostics and preclinical exosome-based therapeutics. During FY26, INOVIQ focused on advancing EXO-OC™, progressing CAR-exosome research and expanding commercial …
Vitasora Health Limited (ASX:VHL) is a healthcare technology company providing connected-care services to healthcare providers in the United States. The company combines clinical care teams, patient engagement programs, connected medical devices and proprietary technology to support Remote Patient Monitoring and Chronic Care Management services. …
• TheOffer Priceis AUD 0.62 per new CDI, with attachingOptionsincluded.
Holista Colltech Ltd (ASX:HCT) shares recently traded at approximately A$0.043, recording a daily decline of 4.44% and trading near the company’s 52-week low range. The share price movement reflects recent market activity and is considered separately from the company’s operational developments. Holista Colltech’s latest …
Recce Pharmaceuticals Ltd (ASX:RCE) shares recently traded at approximately A$0.325, recording a daily decline of 4.41% and trading near the company’s 52-week low range. The share price movement reflects recent market activity and is considered separately from the company’s operational developments. Recce Pharmaceuticals’ latest …
Epiminder Ltd (ASX:EPI) shares recently traded at approximately A$0.25, recording a daily decline of 10.71% and moving near the company’s 52-week low range. The share price movement reflects recent market activity, while the company’s underlying developments remain focused on advancing its clinical program and …
• Resmed shares have declined approximately 24.12% over the past year despite continuedRevenuegrowth and improved financial performance.• The company reported higher FY26 revenue,Earningsgrowth and improved gross margins.• Digital health, connected devices and product innovation remain key areas of development.• Resmed continuedShareholderreturns through dividends and …
• Pro Medicus shares have declined approximately 48.65% over the past year despite continuedBusinessexpansion and technology adoption.• The company reported growth in revenue, profit after tax and new contract activity during FY26.• AI, cloud adoption and healthcare imagingDemandremain key areas of development.• Pro Medicus …
• The company's activities centre on remote pregnancy monitoring, digital maternity workflows and clinical partnerships.